Resumen

TORO VASQUEZ, Juan Pablo  y  MADRID VELEZ, Jorge Alberto. Gastrointestinal stromal tumors (GIST): Role of the surgeon in the molecular medicine era. Iatreia [online]. 2010, vol.23, n.3, pp.268-277. ISSN 0121-0793.

Gastrointestinal stromal tumors (GISTs) are a group of non-epithelial neoplasms that affect the gastrointestinal tract and the mesentery. They are characterized by specific histological and immunohistochemical patterns. Until 1983 GISTs were mistakenly classified as leiomyomas, leiomyoblastomas, and leiomyosarcomas. In that year Mazur and Clark introduced the term ''stromal tumor''. These neoplasms constitute less than 1% of gastrointestinal malignancies and 5% of all sarcomas. Their incidence is 0.68/100.000. It has been demonstrated that GISTs are the result of gain-of-function mutations of c-Kit and PDGFRα protoncogenes. They can appear anywhere from the esophagus to 1 Residente de Cirugía General, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia 1 Residente de Cirugía General, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia. 2 Cirujano Oncólogo, Profesor de Cirugía General, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia. Correspondencia: Jorge Madrid Vélez; jamadrid@une.net.co Recibido: agosto 10 de 2009 Aceptado: abril 26 de 2010 the anus. Clinical manifestations depend on their location and size. Treatment of primary GISTs is surgical but in the advanced stages they may be treated with imatinib mesylate, an effective, molecularly targeted therapy. Adjuvant and neoadjuvant therapy are a controversial issue. This article is an update on GISTs based on the available literature.

Palabras clave : GIST; Imatinib mesylate; Laparoscopic surgery; Gastrointestinal stromal tumors.

        · resumen en Español     · texto en Español     · Español ( pdf )